Literature DB >> 27698132

Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus.

Wenqian He1, Gene S Tan1, Caitlin E Mullarkey1, Amanda J Lee2, Mannie Man Wai Lam3, Florian Krammer1, Carole Henry4, Patrick C Wilson4, Ali A Ashkar2, Peter Palese5, Matthew S Miller6.   

Abstract

The generation of strain-specific neutralizing antibodies against influenza A virus is known to confer potent protection against homologous infections. The majority of these antibodies bind to the hemagglutinin (HA) head domain and function by blocking the receptor binding site, preventing infection of host cells. Recently, elicitation of broadly neutralizing antibodies which target the conserved HA stalk domain has become a promising "universal" influenza virus vaccine strategy. The ability of these antibodies to elicit Fc-dependent effector functions has emerged as an important mechanism through which protection is achieved in vivo. However, the way in which Fc-dependent effector functions are regulated by polyclonal influenza virus-binding antibody mixtures in vivo has never been defined. Here, we demonstrate that interactions among viral glycoprotein-binding antibodies of varying specificities regulate the magnitude of antibody-dependent cell-mediated cytotoxicity induction. We show that the mechanism responsible for this phenotype relies upon competition for binding to HA on the surface of infected cells and virus particles. Nonneutralizing antibodies were poor inducers and did not inhibit antibody-dependent cell-mediated cytotoxicity. Interestingly, anti-neuraminidase antibodies weakly induced antibody-dependent cell-mediated cytotoxicity and enhanced induction in the presence of HA stalk-binding antibodies in an additive manner. Our data demonstrate that antibody specificity plays an important role in the regulation of ADCC, and that cross-talk among antibodies of varying specificities determines the magnitude of Fc receptor-mediated effector functions.

Entities:  

Keywords:  ADCC; Fc receptor; NK cell; antibody; influenza virus

Mesh:

Substances:

Year:  2016        PMID: 27698132      PMCID: PMC5081650          DOI: 10.1073/pnas.1609316113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

Review 1.  The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein.

Authors:  Marit Kramski; Ivan Stratov; Stephen J Kent
Journal:  AIDS       Date:  2015-01-14       Impact factor: 4.177

2.  Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.

Authors:  David J DiLillo; Peter Palese; Patrick C Wilson; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

3.  Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.

Authors:  David J DiLillo; Jeffrey V Ravetch
Journal:  Cell       Date:  2015-05-11       Impact factor: 41.582

4.  Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children.

Authors:  Mary Dawn T Co; Masanori Terajima; Stephen J Thomas; Richard G Jarman; Kamonthip Rungrojcharoenkit; Stefan Fernandez; In-Kyu Yoon; Darunee Buddhari; John Cruz; Francis A Ennis
Journal:  Viral Immunol       Date:  2014-08-20       Impact factor: 2.257

5.  Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.

Authors:  Arnold S Monto; Joshua G Petrie; Rachel T Cross; Emileigh Johnson; Merry Liu; Weimin Zhong; Min Levine; Jacqueline M Katz; Suzanne E Ohmit
Journal:  J Infect Dis       Date:  2015-04-08       Impact factor: 5.226

6.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

7.  Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies.

Authors:  Sinthujan Jegaskanda; Emma R Job; Marit Kramski; Karen Laurie; Gamze Isitman; Robert de Rose; Wendy R Winnall; Ivan Stratov; Andrew G Brooks; Patrick C Reading; Stephen J Kent
Journal:  J Immunol       Date:  2013-01-14       Impact factor: 5.422

8.  Characterization of variable-region genes and shared crossreactive idiotypes of antibodies specific for antigens of various influenza viruses.

Authors:  T M Moran; M Monestier; A C Lai; G Norton; M A Reale; M A Thompson; J L Schulman; R Riblet; C A Bona
Journal:  Viral Immunol       Date:  1987       Impact factor: 2.257

9.  Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.

Authors:  Matthew S Miller; Thomas J Gardner; Florian Krammer; Lauren C Aguado; Domenico Tortorella; Christopher F Basler; Peter Palese
Journal:  Sci Transl Med       Date:  2013-08-14       Impact factor: 17.956

10.  Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.

Authors:  Teddy John Wohlbold; Raffael Nachbagauer; Haoming Xu; Gene S Tan; Ariana Hirsh; Karl A Brokstad; Rebecca J Cox; Peter Palese; Florian Krammer
Journal:  mBio       Date:  2015-03-10       Impact factor: 7.867

View more
  87 in total

1.  Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.

Authors:  Guha Asthagiri Arunkumar; Andriani Ioannou; Teddy John Wohlbold; Philip Meade; Sadaf Aslam; Fatima Amanat; Juan Ayllon; Adolfo García-Sastre; Florian Krammer
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

2.  Influenza-infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem.

Authors:  Elene Clemens; Davide Angeletti; Beth C Holbrook; Masaru Kanekiyo; Matthew J Jorgensen; Barney S Graham; Jonathan Yewdell; Martha A Alexander-Miller
Journal:  JCI Insight       Date:  2020-03-12

Review 3.  Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential for a Universal Influenza Vaccine.

Authors:  James E Crowe
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

4.  Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.

Authors:  Weina Sun; Ericka Kirkpatrick; Megan Ermler; Raffael Nachbagauer; Felix Broecker; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

5.  Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus.

Authors:  Maya Sangesland; Larance Ronsard; Samuel W Kazer; Julia Bals; Seyhan Boyoglu-Barnum; Ashraf S Yousif; Ralston Barnes; Jared Feldman; Maricel Quirindongo-Crespo; Patrick M McTamney; Daniel Rohrer; Nils Lonberg; Bryce Chackerian; Barney S Graham; Masaru Kanekiyo; Alex K Shalek; Daniel Lingwood
Journal:  Immunity       Date:  2019-09-25       Impact factor: 31.745

6.  Differential requirements for FcγR engagement by protective antibodies against Ebola virus.

Authors:  Stylianos Bournazos; David J DiLillo; Arthur J Goff; Pamela J Glass; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

7.  Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells.

Authors:  Sai Priya Anand; Jérémie Prévost; Sophie Baril; Jonathan Richard; Halima Medjahed; Jean-Philippe Chapleau; William D Tolbert; Sharon Kirk; Amos B Smith; Bruce D Wines; Stephen J Kent; P Mark Hogarth; Matthew S Parsons; Marzena Pazgier; Andrés Finzi
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

Review 8.  Immunological responses to influenza vaccination: lessons for improving vaccine efficacy.

Authors:  Taia T Wang; Stylianos Bournazos; Jeffrey V Ravetch
Journal:  Curr Opin Immunol       Date:  2018-05-10       Impact factor: 7.486

9.  A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies.

Authors:  Mark J Bailey; Felix Broecker; Paul E Leon; Gene S Tan
Journal:  J Vis Exp       Date:  2018-02-23       Impact factor: 1.355

10.  Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.

Authors:  E R Job; M Schotsaert; L I Ibañez; A Smet; T Ysenbaert; K Roose; M Dai; C A M de Haan; H Kleanthous; T U Vogel; X Saelens
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.